Policy Environment and Development Trends of China's Veterinary Drug Industry in the First Half of 2025

The 2025 No. 1 Central Document emphasized support for the stable development of the animal husbandry sector, while simultaneously elevating the regulatory oversight of the veterinary drug industry to an unprecedented level.

In the production phase, the new version of the veterinary drug GMP standards has set a high barrier for enterprises. For instance, the production of sterile veterinary drugs and veterinary biological products now requires not only stringent environmental cleanliness standards but also newly introduced dynamic monitoring requirements. This measure significantly raises the production thresholds and operational costs for enterprises, compelling them to invest substantial resources in upgrading production facilities, enhancing staff expertise, and improving quality management systems.

In the distribution phase, veterinary drug operators are required to establish more comprehensive quality management systems. Starting from the procurement stage, strict control over product quality is essential to ensure that veterinary drugs are sourced from legally compliant manufacturers with complete quality documentation. During storage, appropriate conditions—such as precise control over temperature and humidity—must be maintained according to the characteristics of the drugs. The sales process is equally critical, requiring enterprises to maintain detailed records to achieve full traceability of veterinary drug distribution, enabling swift identification and resolution of quality issues when they arise.

Regulation of the usage phase remains a top priority. The document explicitly calls for strengthened guidance and supervision of veterinary drug use, firmly preventing misuse and irrational application. Regulatory authorities have intensified inspections of farms and breeders, imposing severe penalties for any violations of veterinary drug usage regulations. While these stringent measures increase compliance costs for enterprises to some extent, they hold profound significance for enhancing the overall quality and safety of the veterinary drug industry, safeguarding animal health, and ensuring the safety of livestock products in the long run.

Increased Support for R&D and Innovation

To promote technological innovation and product upgrading in the veterinary drug industry, the state has provided substantial support for research and development. On one hand, government funding for veterinary drug R&D has been increased, with specialized scientific research funds established to provide solid financial backing for enterprises engaged in cutting-edge and innovative veterinary drug projects. For example, Hebei Province’s Notice on Several Measures to Support High-Quality Development of the Biopharmaceutical Industry stipulates that enterprises conducting clinical trial research for new veterinary drugs will receive funding support of 2–5 million yuan, while those obtaining the New Veterinary Drug Registration Certificate will be rewarded with 1–3 million yuan. Similarly, Wuhan City has introduced policies offering rewards of 0.5–2 million yuan for enterprises obtaining new veterinary drug registration certificates and 200,000 yuan for those applying for pet-specific drugs through comparative trials. These tangible incentives have greatly stimulated enterprises’ enthusiasm for R&D.

On the other hand, the state actively encourages collaboration between enterprises, research institutions, and universities in industry-academia-research partnerships. By integrating resources and strengths from various parties, these collaborations foster innovation and collectively address key technical challenges in veterinary drug development. Enterprises contribute market experience and industrial capabilities, while research institutions and universities offer strong scientific expertise and talent. Such close cooperation enables complementary advantages, accelerates the transformation and application of research outcomes, and drives technological progress in the veterinary drug industry.